Benefits outweigh harms of aspirin therapy

Prophylactic aspirin therapy of at least 5 years’ duration has a favorable benefit-harm profile, primarily because of its effectiveness in preventing colorectal and other cancers, according to a...

Field of Interest: Gastroentero...
Type: News Item

Benefits outweigh harms of aspirin therapy

Prophylactic aspirin therapy of at least 5 years’ duration has a favorable benefit-harm profile, primarily because of its effectiveness in preventing colorectal and other cancers, according to a...

Field of Interest: Oncology
Type: News Item

Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Oncology
Type: News Item

Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Pulmonology
Type: News Item

Recent use of oral contraceptives linked to breast cancer

Women who recently used oral contraceptives had a 50% greater chance of developing breast cancer than that of women who formerly used or never used oral contraceptives, according to a case-control...

Field of Interest: Oncology
Type: News Item

Stage esophageal cancer after neoadjuvant chemo

Among patients with resectable esophageal adenocarcinoma, tumor stage after completion of neoadjuvant chemotherapy is a much more important predictor of survival than is initial tumor stage at...

Field of Interest: Oncology
Type: News Item

Stage esophageal cancer after neoadjuvant chemo

Among patients with resectable esophageal adenocarcinoma, tumor stage after completion of neoadjuvant chemotherapy is a much more important predictor of survival than is initial tumor stage at...

Field of Interest: Gastroentero...
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.